Company: BIAF
Filing Date: 2025-05-07
Form Type: 424B4
Source: 0001641172-25-008977
Chunk: 185

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-07
Form: 424B4
Chunk 185
---
58 |
| Placement Agent fees(1)            |     | $ |                         0.0256 |     | $ |                  0.02504 |     | $ |   258,672.04 |
| Proceeds to us, before expenses(2) |     | $ |                         0.2944 |     | $ |                  0.28796 |     | $ | 2,974,728.54 |

We have agreed to pay the Placement Agent a total
cash fee equal to 8.0% of the gross proceeds of this offering. We will also reimburse the Placement Agent’s legal fees and expenses
in an amount up to $120,000. We estimate the total offering expenses of this offering that will be payable by us, excluding the
Placement Agent fees and expenses, will be approximately $163,000. After deducting the Placement Agent fees and our estimated
offering expenses, we expect the net proceeds from this offering to be approximately $2.7 million.

Placement Agent Warrants

We have also agreed to issue to the Placement Agent (or its designees) Placement Agent Warrants to purchase up to 304,687 shares of Common Stock. The Placement Agent Warrants will have substantially the same terms as the May 2025 Warrants described above, including that they will have an exercise price of $0.352 per share (representing 110% of the combined public offering price per share of Common Stock and accompanying May 2025 Warrant, except that the Placement Agent Warrants will not have any anti-dilution (other than protection against pro rata distributions or share combinations) provisions, will not include a provision to increase the number of shares underlying the Placement Agent Warrants upon the occurrence of a reverse stock split, will be immediately exercisable and will have a termination date that will be five years from the commencement of the sales pursuant to this offering. In accordance with FINRA Rule 5110(e), the Placement Agent may not sell, transfer, assign, pledge, or hypothecate the Placement Agent Warrant or the securities underlying such warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such warrants or the underlying securities for a period of 180 days following the date of commencement of sales pursuant to this public offering. The Placement Agent Warrants are registered on the registration statement of which this prospectus is a part. The form of the Placement Agent